Trial Profile
A reterospective study evaluating the early administration of monoclonal antibody mABs for nosocomial SARS-CoV-2 infections in yet asymptomatic patients at high risk for a severe course of COVID-19 disease in real-life settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2021 New trial record
- 09 Jul 2021 Results published in the Infection